SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic

Journal of Clinical and Translational Endocrinology

Volumn 13, Issue , 2018, Pages 46-47

  Sung, Jasper ^a   Padmanabhan, Suja ^a,b   Gurung, Seema ^a   Inglis, Sally ^a   Vicaretti, Mauro ^a   Begg, Lindy ^a   Cheung, N Wah ^a,b   Girgis, Christian M ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; AUSTRALIA; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; HIGH RISK POPULATION; HUMAN; LEG AMPUTATION; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 85050072091     PISSN: None     EISSN: 22146237     Source Type: Journal    
DOI: 10.1016/j.jcte.2018.07.002     Document Type: Letter

References (8)

1. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
3. United States Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin, https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf; 2017 [accessed 12 November 2017].
4. Inzucchi, S.E., Iliev, H., Pfarr, E., Zinman, B., Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), e4–e5.
5. Jabbour, S., Seufert, J., Scheen, A., Bailey, C.J., Karup, C., Langkilde, A.M., Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20:30 (2017), 620–628.
6. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information, http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/European_Commission_final_decision/WC500227101.pdf; 2017 [accessed 12 November 2017].
7. Blackwelder, W.C., Proving the Null Hypothesis. Control Clin Trials 3 (1982), 345–353.
8. Adler, A.I., Boyko, E.J., Ahroni, J.H., Smith, D.G., Lower-extremity amputations in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22:7 (1999), 1029–1035.